AKEBIA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Loss Position
AKEBIA THERAPEUTICS, INC. (AKBA) had Debt Securities, Available-for-sale, Unrealized Loss Position of $49.94 million as of 2020-06-30, per its 10-Q filed 2020-08-10.
Discontinued › Notes › Investments › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2020-08-10
- 2020-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $49.94M.
- 2019-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $10.23M.
- 2019-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $65.53M.
- 2018-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $204.39M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2020-06-30 | $49.94M 10-Q · filed 2020-08-10 |
| 2019-06-30 | $10.23M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $65.53M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $204.39M 10-K · filed 2020-03-12 |
| 2018-09-30 | $223.31M 10-Q · filed 2018-11-08 |
| 2017-12-31 | $233.52M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |